Literature DB >> 19242094

Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors.

Benito Anton1, Alberto Salazar, Anabel Flores, Maura Matus, Rodrigo Marin, Jorge-Alberto Hernandez, Philippe Leff.   

Abstract

Current pharmacotherapies for treating morphine/heroin dependence are designed to substitute or block addiction by targeting the drug itself rather than the brain. The heroin addict is still being exposed to addictive opiates, and consequently may develop tolerance to and experience withdrawal and drug's toxic effects from the treatment with high incidence of relapse to addictive drug consumption. As for other drugs of abuse, an alternative approach for morphine/heroin addiction is an antibody-based antagonism of heroin's brain entry. This review summarizes the literature examining important aspects of neurobiological and pharmacological processes involved in opiate dependence. Thereafter, classical pharmacological interventions for opiate dependence treatment and its major clinical limitations are reviewed. Finally, relevant preclinical studies are examined for comparisons in the design, use, immunogenic profile and efficacy of several models of morphine/heroin vaccine as immunologic interventions on the pharmacokinetics and behavioral of morphine/heroin in the rat as animal model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242094     DOI: 10.4161/hv.5.4.7556

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  26 in total

Review 1.  Vaccines targeting drugs of abuse: is the glass half-empty or half-full?

Authors:  Kim D Janda; Jennifer B Treweek
Journal:  Nat Rev Immunol       Date:  2011-12-16       Impact factor: 53.106

Review 2.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

3.  Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.

Authors:  Katherine E Cornish; Andrew C Harris; Mark G LeSage; Dan E Keyler; Danielle Burroughs; Cathy Earley; Paul R Pentel
Journal:  Int Immunopharmacol       Date:  2011-07-28       Impact factor: 4.932

Review 4.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 5.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

6.  Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Authors:  Gary R Matyas; Alexander V Mayorov; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Malliga R Iyer; Fuying Li; Zoltan Beck; Kim D Janda; Carl R Alving
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

7.  An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia.

Authors:  M Pravetoni; M Le Naour; T M Harmon; A M Tucker; P S Portoghese; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-01-18       Impact factor: 4.030

8.  Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

Authors:  Candy S Hwang; Paul T Bremer; Cody J Wenthur; Sam On Ho; SuMing Chiang; Beverly Ellis; Bin Zhou; Gary Fujii; Kim D Janda
Journal:  Mol Pharm       Date:  2018-02-19       Impact factor: 4.939

9.  Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.

Authors:  Suzette M Evans; Richard W Foltin; Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Kim D Janda; Stephen M Kaminsky; Ronald G Crystal
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

10.  Vaccines in the Treatment of Substance Abuse.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  Focus (Am Psychiatr Publ)       Date:  2011-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.